Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KC 1036

Next Previous
Drug Profile

KC 1036

Alternative Names: KC-1036

Latest Information Update: 26 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KONRUNS Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase II Ewing's sarcoma
  • Phase I/II Digestive system neoplasms

Most Recent Events

  • 19 Aug 2024 Phase-II clinical trials in Ewing's Sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (PO) (NCT06564272)
  • 05 Feb 2024 Phase-III clinical trials in Squamous cell cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO) (NCT06194734)
  • 08 Jan 2024 Beijing Konruns Pharmaceutical plans a phase III trial for Oesophageal cancer (Late stage disease, Second line therapy or greater, Recurrent, Metastatic disease) in January 2024 (NCT06194734)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top